Game-changer for kidney disease: Novartis’ Fabhalta wins FDA approval in record time
Novartis has reached a pivotal moment in the treatment of rare kidney diseases with the US Food and Drug Administration (FDA) granting accelerated approval for ... Read More
FDA approves Novartis’ Cosentyx for hidradenitis suppurativa treatment
Novartis, a global leader in immuno-dermatology and rheumatology, announced the U.S. Food and Drug Administration's approval of Cosentyx (secukinumab) for treating adults with moderate to ... Read More
Novartis reports positive results for Aimovig in phase 2 episodic migraine trial
Novartis said that a five-year phase 2 clinical trial of migraine prevention drug Aimovig (erenumab-aooe) has delivered strong long-term safety and efficacy results in patients ... Read More